Results of Operations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): March 30, 2022   VolitionRx Limited (Exact name of registrant as specified in its charter)   Delaware   001-36833   91-1949078 (State or other jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification Number)   13215 Bee Cave Parkway Suite 125 , Galleria Oaks B Austin , Texas 78738 (Address of principal executive offices and Zip Code)   +1 ( 646 ) 650-1351 (Registrant’s telephone number, including area code)   Not applicable (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)    ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)    ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Trading Symbol(s)   Name of Each Exchange on which Registered Common Stock, par value $0.001 per share   VNRX   NYSE American, LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         VOLITIONRX LIMITED Form 8-K Current Report   Item 2.02. Results of Operations and Financial Condition.   The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.   On March 30, 2022, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for its quarter and fiscal year ended December 31, 2021.  The Company also confirmed its conference call to be held on March 31, 2022 at 8:00 a.m. U.S. Eastern Time.  Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.   Item 9.01. Financial Statements and Exhibits.   (d) Exhibits.   Exhibit Number   Description 99.1   Press Release of VolitionRx Limited, dated March 30, 2022. 104   Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)     2     SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     VOLITIONRX LIMITED         Date: March 30, 2022 By:   /s/ Cameron Reynolds     Cameron Reynolds       Chief Executive Officer & President       3     EXHIBIT INDEX   Exhibit Number     Description 99.1   Press Release of VolitionRx Limited, dated March 30, 2022.     4